Paragonix Sues Traferox in Marshall on Six Organ Preservation Patents.

The parties and the court

Paragonix Technologies, Inc. v. Traferox Technologies, Inc., No. 2:26-cv-00982 (E.D. Tex., Marshall Division), is a patent infringement complaint filed October 30, 2026. The complaint describes Paragonix as a Delaware corporation with its principal place of business in Waltham, Massachusetts. It alleges, on information and belief, that Traferox is a Canadian corporation located in Mississauga, Ontario. Subject-matter jurisdiction is pleaded under 28 U.S.C. §§ 1331 and 1338. Venue is pleaded under 28 U.S.C. § 1391(c)(3) because Traferox is not a resident of the United States. Personal jurisdiction is pleaded, on information and belief, under the Texas long-arm statute and, in the alternative, under Rule 4(k)(2). The court's docket record lists the case as assigned to District Judge Rodney Gilstrap.

The patents

The complaint asserts six patents that it says Paragonix owns: U.S. Patent 12,543,729, "System for Hypothermic Transport of Samples," issued February 10, 2026; U.S. Patent 12,557,806, also titled "System for Hypothermic Transport of Samples," issued February 24, 2026; U.S. Patent 12,564,187, "Apparatus for Tissue Transport and Preservation," issued March 3, 2026; U.S. Patent 12,610,943, same title, issued April 28, 2026; U.S. Patent 12,660,813, same title, issued June 23, 2026; and U.S. Patent 12,740,557, same title, issued September 22, 2026. The complaint describes the '729 patent as directed to methods for hypothermic transport of donor organs in a portable storage container with a basket that supports the organ and limits its movement, and the '806 patent as directed to a system with a container and an insert that receives and supports the organ, with a lid that helps provide an insulated environment. It describes the '187 and '813 patents as directed to systems for storing or transporting an organ with a transport container, an internal basket or organ container, a shelf or tray holding cooling material above the organ, and a temperature probe or sensor; the '943 patent as directed to methods of maintaining a desired temperature inside such a container, with a basket holding the organ within a bag and cooling material on a shelf above it; and the '557 patent as directed to storage systems with a container, a lid, a tray that holds cooling material, and a temperature sensor. It says the '187, '813, '557, and '943 patents claim priority to the same two provisional applications.

The accused products

The complaint defines the Accused Products as the X°Port Lung Preservation System, the X°Port Heart Preservation System, and the VI°Port Liver Preservation System. It alleges, on information and belief, that Traferox makes, uses, offers to sell, sells, and/or imports those systems in the United States and has sold them to customers in Texas, and it points to instructions for use that it says are intended for distribution in the United States and to a multi-center lung preservation clinical trial that it says included testing in Texas, alleging, on information and belief, that at least a portion of the study is taking place in Dallas, Texas. It incorporates claim charts attached as exhibits for each asserted patent; the claim charts are not available.

Notice and willfulness allegations

The complaint alleges, on information and belief, that Traferox knows of Paragonix's patent portfolio, including the asserted patents. It says that in a September 25, 2023 response to a Paragonix letter, Traferox identified Paragonix's U.S. Patent 11,166,452, which the complaint says is in the same family as the '187, '813, '557, and '943 patents, and that Paragonix identified the two provisional applications in a November 2023 letter. It says a March 12, 2025 Paragonix letter identified U.S. Patents 12,035,708, 12,121,023, and 12,245,586, which it says are in the same family as the '729 and '806 patents, and that Traferox responded on April 4, 2025 that no commercial activity of its X°Port device had occurred in the United States. The complaint alleges that Traferox has since acknowledged that the accused products are sold and used in the United States, that Paragonix marks its own products under 35 U.S.C. § 287 with an internet address associating them with certain of the asserted patents, and, on information and belief, that Traferox knows of that marking, pointing to FDA 510(k) summaries in which it says Traferox listed Paragonix products as predicate devices.

The counts

Each count is pleaded on information and belief. Count One alleges infringement of the '729 patent, including at least claim 1, under 35 U.S.C. § 271(a), (b), and (c), and willfulness. Count Two alleges infringement of the '806 patent, including at least claims 9 and 21, under § 271(a), (b), and (c), and willfulness. Count Three alleges infringement of the '187 patent, including at least claim 1, under § 271(a), (b), and (c), and willfulness. Count Four alleges infringement of the '943 patent, including at least claims 1, 18, 19, and 20, under § 271(a), (b), and (c), and willfulness. Count Five alleges infringement of the '813 patent, including at least claim 1, under § 271(a), (b), and (c), and willfulness. Count Six alleges infringement of the '557 patent, including at least claims 1 and 11, under § 271(a), (b), and (c), and willfulness. Each count seeks damages, including under § 284, injunctive relief under § 283, and exceptional-case fees under § 285.

Relief sought

The prayer asks for a judgment of infringement; a permanent injunction; a judgment that the infringement was and is willful; damages including lost profits and/or a reasonable royalty, with interest; willfulness damages; an exceptional-case finding with costs and attorneys' fees under 35 U.S.C. § 285; and further relief. The complaint demands a jury.

Docket

Through November 5, 2026, the docket shows the complaint, the patent and trademark form (AO 120), the plaintiff's disclosure statement, a summons request, and a summons issued as to Traferox Technologies, Inc. Watch for proof of service, the defendant's answer, counterclaims, or a Rule 12 motion. The case can end at any time, including by settlement or voluntary dismissal.